Lineage Cell Therapeutics
Most recent annual filing: 2026-03-05
- COR1 readout2026COR1 readout, 2026, notable
- LCTX corporate update3Q 2026LCTX corporate update, 3Q 2026, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
OPC1
Cell Target: oligodendrocyte progenitor cells
ReSonance
ANP1 Cell Target: auditory neuron progenitor cells
- Auditory Neuropathy
PNC1
Cell Target: photoreceptors
RND1
Cell Target: hypoimmune iPSC
- Undisclosed indication
Technology platforms
AlloSCOPE
Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering platform; proprietary in-house cell-based manufacturing platform supporting development of cell replacement therapies for serious medical conditions
Biotech Distilled coverage (1)
- 2026-08-17 Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.